CRO Regulatory Services for Generics and Biosimilars Drugs Market Report 2020-2030
Discover sales predictions for the world market and submarkets
- By Services
- Regulatory Writing and Publishing
- Clinical Trial Application and Product Registration
- Regulatory Consulting
- Legal Representation
- Other Regulatory Services
- By Application
- Oncology
- Cardiology
- Infectious Disease
- Metabolic Disorders
- Others
- By Clinical Phase
- Preclinical
- Phase I
- Phase II
- Phase III
- Phase IV
- By End User
- Pharmaceutical Companies
- Biotechnology Companies
- Government Institutes
- Others
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, U.S., Germany, UK and India, China in particular, will continue to achieve high revenue growth to 2030.
Leading companies and the potential for market growth
Overall world revenue for CRO Regulatory Services for Generics and Biosimilar Drugs Market will surpass $xx million in 2020, our work calculates. We predict strong revenue growth through to 2030.
Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the CRO Regulatory Services for Generics and Biosimilar Drugs Market report helps you
In summary, our 500+ page report provides you with the following knowledge:
- Revenue forecasts to 2030 for CRO Regulatory Services for Generics and Biosimilar Drugs Market, with forecasts for Technology and Application, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
- Revenue forecasts to 2030 for 5 regional and 16 key national markets – See forecasts for the CRO Regulatory Services for Generics and Biosimilar Drugs market in North America, Europe, Asia-Pacific, Latin America and Middle East and Africa. Also forecasted is the market in the US, Canada,, Brazil, Mexico, Germany, France, UK, Italy, Spain, Russia, China, India, Japan, Australia, GCC Countries and South Africa.
- Prospects for established firms and those seeking to enter the market– including company profiles for 11 of the major companies involved in the CRO Regulatory Services for Generics and Biosimilar Drugs Market. Some of the company’s profiles in this report include:
- IQVIA (Quintiles Transnational)
- ICON plc
- Pharmaceutical Product Development (PPD)
- Covance, Inc.
- Genpact Ltd.
- Criterium, Inc.
- Accell Clinical Research
- Charles River Laboratories International
- Medpace, Inc.
- Wuxi AppTec.
- Syneos Health
Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
The publisher is using a password system to access all reports. Single user (non-printable) and departmental licenses expires after 12 month period. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.
- 1. Report Overview
- 1.1 Overview of CRO Regulatory Services for Generics and Biosimilars Drugs: R&D, Industry and Market
- 1.2 Why You Should Read this Report
- 1.3 How This Study Delivers
- 1.4 Main Questions Answered by the Analysis
- 1.5 Who is This Investigation For?
- 1.6 Method of Research and Analysis
- 1.7 Recovery Scenarios
- 1.8 Frequently Asked Questions (FAQs)
- 1.9 Associated Visiongain Reports
- 1.10 About Visiongain
- 2. Executive Summary
- 2.1 Key Market Facts: CRO regulatory services for generics and biosimilars drugs 2019-2030
- 2.2 Geographical Scenario
- 2.3 Companies in the Market
- 3. Introduction to CRO Regulatory Services for Generics and Biosimilars Drugs
- 3.1 What are Contract Research Organizations (CROs)
- 3.2 CRO Services
- 3.2.1 Medical Function
- 3.2.2 Regulatory Application Team
- 3.2.3 Clinical Operations
- 3.2.4 Data management:
- 3.2.5 Biostatistics
- 3.2.6 Medical Writing
- 3.2.7 Quality Assurance
- 3.3 Importance of Outsourcing CRO Services
- 4. CRO Regulatory Services for Generics and Biosimilar Drugs: Qualitative Analysis 2020-2030
- 4.1 Market Drivers Analysis: 2020-2030
- 4.1.1 Growing Demand for Contract Manufacturing Services
- 4.1.2 Focus On Core Competencies By Pharmaceutical and Biopharmaceutical Companies
- 4.1.3 Rise in Demand for Biosimilars and Generics
- 4.2 Market Restraints Analysis: 2020-2030
- 4.2.1 Project Delays and Cancellations
- 4.2.2 Shortage of Skilled Professionals
- 4.3 Market Opportunities Analysis: 2020-2030
- 4.3.1 Favourable Shift of Regulatory Landscape
- 4.3.2 Pricing Pressures and Intense Competition Among Pharmaceutical and Biopharmaceutical Companies
- 4.3.3 CROs in Emerging Market
- 4.4 Market Trends: 2020-2030
- 4.4.1 Advantages of Outsourcing
- 4.4.2 Growing Trend to Outsource the Regulatory Affairs
- 5. CRO Regulatory Services Industry Study, 2020-2030
- 5.1 CRO Regulatory Services Industry: Porters Five Forces Analysis, 2020-2030
- 5.1.1 Bargaining Power of Supplier: Low
- 5.1.2 Bargaining Power of Buyer: Moderate
- 5.1.3 Competitive Rivalry: High
- 5.1.4 Threat of New Entrants: Moderate
- 5.1.5 Threat of Substitutes: Low
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.1.1 Outsourcing Improves Time to Launch Product in the Market
- 5.2.1.2 Global Demand for Affordable Biopharmaceuticals has Never Been Greater
- 5.2.1.3 Adoption of Biosimilar will be Proportional to the Rate of Discount
- 5.2.1.4 Approval Pathways are Now Established in Developed Markets
- 5.2.1.5 Manufacturers Get Access to Specialised Technologies
- 5.2.1.6 Shift Towards Emerging Markets as Favourable Outsourcing Destinations
- 5.2.2 Weaknesses
- 5.2.2.1 Complexity of Protein Molecules Leads to Technical Challenges
- 5.2.2.2 Doctor and Patient Confidence May Take Time
- 5.2.3 Opportunities
- 5.2.3.1 Dynamic Change: Emerging Markets are Major Biosimilar Developers
- 5.2.3.2 Market Opportunities from Patent Expiries and a Well-stocked Pipeline
- 5.2.3.3 Many Companies Cannot Afford In-house Capabilities
- 5.2.3.4 Changing World Demographics
- 5.2.4 Threats
- 5.2.4.1 Biobetters Offer a Serious Threat to the Production and Uptake of Biosimilars
- 5.3 Regulatory Framework Analysis
- 5.4 PEST Analysis: CRO Regulatory Services for Generics and Biosimilars Drugs Market 2020-2030
- 5.4.1 Political Issues: Stringent Regulations Hurdles to Market Entry
- 5.4.2 Economic Pressures Raise Demand for Generic and Biosimilar Drugs
- 5.4.2.1 Fragmentation of the Market Could Limit Individual Revenues
- 5.4.3 Social Factors: Driving or Restraining the Market?
- 5.4.4 Technological Factors Concentrate on Reducing Costs and Increasing Ease of Production
- 6. CRO Regulatory Services for Generics and Biosimilars Drugs Market: Impact of COVID-19
- 7. Global CRO Regulatory Services for Generics and Biosimilar Drugs Market Landscape 2020-2030
- 7.1 Global CRO Regulatory Services for Generics and Biosimilar Drugs Market
- 7.1.1 Global CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
- 7.2 Market Share Analysis By Services
- 7.3 Market Share Analysis By Region 2020-2030
- 8. CRO Regulatory Services for Generics and Biosimilar Drugs Market by Services, 2020-2030
- 8.1 Market Overview
- 8.2 CRO Regulatory Services for Generics and Biosimilar Drugs Market by Services, Market Forecast 2020-2030
- 8.2.1 Recovery Scenarios (V, U, W, L): CRO Regulatory Services for Generics and Biosimilar Drugs Market by Services, 2020-2030
- 8.3 Market Share of CRO Regulatory Services for Generics and Biosimilar Drugs
- 8.3.1 Regulatory Writing and Publishing
- 8.3.2 Clinical Trial Application and Product Registration
- 8.3.3 Regulatory Consulting
- 8.3.4 Legal Representation
- 8.3.5 Other Regulatory Affairs
- 9. CRO Regulatory Services for Generics and Biosimilar Drugs Market by Application, 2020-2030
- 9.1 Market Overview
- 9.2 Market Forecast 2020-2030
- 9.2.1 Recovery Scenarios (V, U, W, L): CRO Regulatory Services for Generics and Biosimilar Drugs Market by Application, 2020-2030
- 9.3 Market Share of CRO Regulatory Services for Generics and Biosimilar Drugs
- 9.3.1 Oncology
- 9.3.2 Cardiology
- 9.3.3 Infectious Diseases
- 9.3.4 Metabolic Disorders
- 9.3.5 Other Applications
- 10. CRO Regulatory Services for Generics and Biosimilar Drugs Market by Clinical Phase, 2020-2030
- 10.1 Market Overview
- 10.2 Market Forecast 2020-2030
- 10.2.1 Recovery Scenarios (V, U, W, L): CRO Regulatory Services for Generics and Biosimilar Drugs Market by Clinical Phase, 2020-2030
- 10.3 Market Share of CRO Regulatory Services for Generics and Biosimilar Drugs
- 10.3.1 Pre-clinical Phase
- 10.3.2 Phase I
- 10.3.3 Phase II
- 10.3.4 Phase III
- 10.3.5 Phase IV
- 11. CRO Regulatory Services for Generics and Biosimilar Drugs Market by End User, 2020-2030
- 11.1 Market Overview
- 11.2 Market Forecast 2020-2030
- 11.2.1 Recovery Scenarios (V, U, W, L): CRO Regulatory Services for Generics and Biosimilar Drugs Market by End Use, 2020-2030
- 11.3 Market Share of CRO Regulatory Services for Generics and Biosimilar Drugs
- 11.3.1 Pharmaceutical Companies
- 11.3.2 Biotechnology Companies
- 11.3.3 Government Institutes
- 11.3.4 Others
- 12. Leading National Markets 2020-2030
- 12.1 Geographical Breakdown of the World CRO Regulatory Services for Generics and Biosimilars Drugs Market
- 12.2 Global CRO Regulatory Services for Generics and Biosimilars Drugs Market: Regional Forecast 2020-2030
- 12.3 How Will Regional Market Shares Change by 2030?
- 13. North America CRO Regulatory Services for Generics and Biosimilars Drugs Market, 2020-2030
- 13.1 North America CRO Regulatory Services for Generics and Biosimilar Drugs Market by Service, 2020 to 2030
- 13.1.1 Recovery Scenarios (V, U, W, L): North America CRO Regulatory Services for Generics and Biosimilar Drugs Market by Service, 2020 to 2030
- 13.2 North America CRO Regulatory Services for Generics and Biosimilar Drugs Market by Application, 2020 to 2030
- 13.2.1 Recovery Scenarios (V,U,W,L): North America CRO Regulatory Services for Generics and Biosimilar Drugs Market by Application, 2020 to 2030
- 13.3 North America CRO Regulatory Services for Generics and Biosimilar Drugs Market by Clinical Phase, 2020 to 2030
- 13.3.1 Recovery (V,U,W,L) Scenarios: North America CRO Regulatory Services for Generics and Biosimilar Drugs Market by Clinical Phase, 2020 to 2030
- 13.4 North America CRO Regulatory Services for Generics and Biosimilar Drugs Market by End-Use, 2020 to 2030
- 13.4.1 Recovery (V,U,W,L) Scenarios: North America CRO Regulatory Services for Generics and Biosimilar Drugs Market by End-Use, 2020 to 2030
- 13.5 North America CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
- 13.6 US CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
- 13.6.1 U.S. CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
- 13.7 Canada CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
- 13.7.1 Canada CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
- 14. Europe CRO Regulatory Services for Generics and Biosimilars Drugs Market, 2020-2030
- 14.1 Europe CRO Regulatory Services for Generics and Biosimilar Drugs Market by Service, 2020 to 2030
- 14.1.1 Recovery Scenarios (V, U, W, L): Europe CRO Regulatory Services for Generics and Biosimilar Drugs Market by Service, 2020 to 2030
- 14.2 Europe CRO Regulatory Services for Generics and Biosimilar Drugs Market by Application, 2020 to 2030
- 14.2.1 Recovery Scenarios (V,U,W,L): Europe CRO Regulatory Services for Generics and Biosimilar Drugs Market by Application, 2020 to 2030
- 14.3 Europe CRO Regulatory Services for Generics and Biosimilar Drugs Market by Clinical Phase, 2020 to 2030
- 14.3.1 Recovery (V,U,W,L) Scenarios: Europe CRO Regulatory Services for Generics and Biosimilar Drugs Market by Clinical Phase, 2020 to 2030
- 14.4 Europe CRO Regulatory Services for Generics and Biosimilar Drugs Market by End-Use, 2020 to 2030
- 14.4.1 Recovery (V,U,W,L) Scenarios: Europe CRO Regulatory Services for Generics and Biosimilar Drugs Market by End-Use, 2020 to 2030
- 14.5 Europe CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
- 14.6 Germany CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
- 14.6.1 Germany CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
- 14.7 UK CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
- 14.7.1 UK CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
- 14.8 French CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
- 14.8.1 French CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
- 14.9 Italian CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
- 14.9.1 Italian CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
- 14.10 Spanish CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
- 14.10.1 Spanish CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
- 14.11 Russia CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
- 14.11.1 Russian CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
- 14.12 Rest of Europe CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
- 14.12.1 Rest of Europe CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
- 15. Asia Pacific CRO Regulatory Services for Generics and Biosimilars Drugs Market 2020-2030
- 15.1 Asia Pacific CRO Regulatory Services for Generics and Biosimilar Drugs Market by Service, 2020 to 2030
- 15.1.1 Recovery Scenarios (V, U, W, L): Asia Pacific CRO Regulatory Services for Generics and Biosimilar Drugs Market by Service, 2020 to 2030
- 15.2 Asia Pacific CRO Regulatory Services for Generics and Biosimilar Drugs Market by Application, 2020 to 2030
- 15.2.1 Recovery Scenarios (V,U,W,L): Asia Pacific CRO Regulatory Services for Generics and Biosimilar Drugs Market by Application, 2020 to 2030
- 15.3 Asia Pacific CRO Regulatory Services for Generics and Biosimilar Drugs Market by Clinical Phase, 2020 to 2030
- 15.3.1 Recovery (V,U,W,L) Scenarios: Asia Pacific CRO Regulatory Services for Generics and Biosimilar Drugs Market by Clinical Phase, 2020 to 2030
- 15.4 Asia Pacific CRO Regulatory Services for Generics and Biosimilar Drugs Market by End-Use, 2020 to 2030
- 15.4.1 Recovery (V,U,W,L) Scenarios: Asia Pacific CRO Regulatory Services for Generics and Biosimilar Drugs Market by End-Use, 2020 to 2030
- 15.5 Asia Pacific CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
- 15.6 Japanese CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
- 15.6.1 Japanese CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
- 15.7 Chinese CRO Regulatory Services for Generics and Biosimilars Drugs Market 2020-2030
- 15.7.1 Chinese CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
- 15.8 Indian CRO Regulatory Services for Generics and Biosimilars Drugs Market 2020-2030
- 15.8.1 Indian CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
- 15.9 Australia CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
- 15.9.1 Australia CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
- 15.10 Rest of Asia Pacific CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
- 15.10.1 Rest of Asia Pacific CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
- 16. Latin America CRO Regulatory Services for Generics and Biosimilars Drugs Market 2020-2030
- 16.1 Latin America CRO Regulatory Services for Generics and Biosimilar Drugs Market by Service, 2020 to 2030
- 16.1.1 Recovery Scenarios (V, U, W, L): Latin America CRO Regulatory Services for Generics and Biosimilar Drugs Market by Service, 2020 to 2030
- 16.2 Latin America CRO Regulatory Services for Generics and Biosimilar Drugs Market by Application, 2020 to 2030
- 16.2.1 Recovery Scenarios (V,U,W,L): Latin America CRO Regulatory Services for Generics and Biosimilar Drugs Market by Application, 2020 to 2030
- 16.3 Latin America CRO Regulatory Services for Generics and Biosimilar Drugs Market by Clinical Phase, 2020 to 2030
- 16.3.1 Recovery (V,U,W,L) Scenarios: Latin America CRO Regulatory Services for Generics and Biosimilar Drugs Market by Clinical Phase, 2020 to 2030
- 16.4 Latin America CRO Regulatory Services for Generics and Biosimilar Drugs Market by End-Use, 2020 to 2030
- 16.4.1 Recovery (V,U,W,L) Scenarios: Latin America CRO Regulatory Services for Generics and Biosimilar Drugs Market by End-Use, 2020 to 2030
- 16.5 Latin America CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
- 16.6 Brazilian CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
- 16.6.1 Brazilian CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
- 16.7 Mexico CRO Regulatory Services for Generics and Biosimilars Drugs Market 2020-2030
- 16.7.1 Mexican CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
- 16.8 Rest of Latin America CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
- 16.8.1 Rest of Latin America CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
- 17. MEA CRO Regulatory Services for Generics and Biosimilars Drugs Market 2020-2030
- 17.1 MEA CRO Regulatory Services for Generics and Biosimilar Drugs Market by Service, 2020 to 2030
- 17.1.1 Recovery Scenarios (V, U, W, L): MEA CRO Regulatory Services for Generics and Biosimilar Drugs Market by Service, 2020 to 2030
- 17.2 MEA CRO Regulatory Services for Generics and Biosimilar Drugs Market by Application, 2020 to 2030
- 17.2.1 Recovery Scenarios (V,U,W,L): MEA CRO Regulatory Services for Generics and Biosimilar Drugs Market by Application, 2020 to 2030
- 17.3 MEA CRO Regulatory Services for Generics and Biosimilar Drugs Market by Clinical Phase, 2020 to 2030
- 17.3.1 Recovery (V,U,W,L) Scenarios: MEA CRO Regulatory Services for Generics and Biosimilar Drugs Market by Clinical Phase, 2020 to 2030
- 17.4 MEA CRO Regulatory Services for Generics and Biosimilar Drugs Market by End-Use, 2020 to 2030
- 17.4.1 Recovery (V,U,W,L) Scenarios: MEA CRO Regulatory Services for Generics and Biosimilar Drugs Market by End-Use, 2020 to 2030
- 17.5 MEA CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
- 17.6 GCC CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
- 17.6.1 GCC CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
- 17.7 South Africa CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
- 17.7.1 South Africa CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
- 17.8 Rest of MEA CRO Regulatory Services for Generics and Biosimilars Drugs Market Forecast 2020-2030
- 17.8.1 Rest of MEA CRO Regulatory Services for Generics and Biosimilar Drugs Market: Recovery Scenarios (V, U, W, L)
- 18. Leading Companies in the CRO Regulatory Services for Generics and Biosimilars Drugs Market
- 18.1 IQVIA
- 18.1.1 IQVIA: Company Snapshot
- 18.1.2 IQVIA: Company Overview
- 18.1.3 IQVIA: Financials, 2015-2019
- 18.1.4 IQVIA: Services
- 18.1.5 IQVIA: Recent Developments
- 18.2 ICON plc.
- 18.2.1 ICON plc.: Company Snapshot
- 18.2.2 ICON plc.: Company Overview
- 18.2.3 ICON plc.: Financial Overview 2015-2019
- 18.2.4 ICON plc.: Services Portfolio
- 18.2.5 ICON plc.: Recent Developments
- 18.3 Pharmaceutical Product Development (PPD)
- 18.3.1 Pharmaceutical Product Development (PPD): Company Snapshot
- 18.3.2 Pharmaceutical Product Development (PPD): Company Overview
- 18.3.3 Pharmaceutical Product Development (PPD): Services Portfolio
- 18.3.4 Pharmaceutical Product Development (PPD): Recent Developments
- 18.4 Covance Inc.
- 18.4.1 Covance Inc.: Company Snapshot
- 18.4.2 Covance Inc.: Company Overview
- 18.4.3 Covance Inc.: Financial Overview
- 18.4.4 Covance Inc.: Services Portfolio
- 18.4.5 Covance Inc.: Recent Developments
- 18.5 Genpact Ltd.
- 18.5.1 Genpact Ltd.: Company Snapshot
- 18.5.2 Genpact Ltd.: Company Overview
- 18.5.3 Genpact Ltd.: Financial Overview
- 18.5.4 Genpact Ltd.: Services Portfolio
- 18.5.5 Genpact Ltd.: Recent Developments
- 18.6 Criterium Inc.
- 18.6.1 Criterium Inc.: Company Snapshot
- 18.6.2 Criterium Inc.: Company Overview
- 18.6.3 Criterium Inc.: Services Portfolio
- 18.6.4 Criterium Inc.: Recent Developments
- 18.7 Accell Clinical Research, LLC
- 18.7.1 Accell Clinical Research, LLC: Company Snapshot
- 18.7.2 Accell Clinical Research, LLC: Company Overview
- 18.7.3 Accell Clinical Research, LLC: Services Portfolio
- 18.7.4 Accell Clinical Research, LLC: Recent Developments
- 18.8 Charles River Laboratories International
- 18.8.1 Charles River Laboratories: Company Snapshot
- 18.8.2 Charles River Laboratories: Company Overview
- 18.8.3 Charles River Laboratories: Financial Overview
- 18.8.4 Charles River Laboratories: Services
- 18.8.5 Charles River Laboratories: Recent Developments
- 18.9 Medpace, Inc.
- 18.9.1 Medpace Inc.: Company Snapshot
- 18.9.2 Medpace Inc.: Company Overview
- 18.9.3 Medpace Inc.: Financial Overview
- 18.9.4 Medpace Inc.: Services Portfolio
- 18.9.5 Medpace Inc.: Recent Developments
- 18.10 WuXi AppTec
- 18.10.1 WuXi AppTec: Company Snapshot
- 18.10.2 WuXi AppTec: Company Overview
- 18.10.3 WuXi AppTec: Financial Overview
- 18.10.4 WuXi AppTec: Services Portfolio
- 18.10.5 WuXi AppTec: Recent Developments
- 18.11 Syneos Health
- 18.11.1 Syneos Health: Company Snapshot
- 18.11.2 Syneos Health: Company Overview
- 18.11.3 Syneos Health: Financial Overview
- 18.11.4 Syneos Health: Services Portfolio
- 18.11.5 Syneos Health: Recent Developments
- 19. Conclusions
- 19.1 CRO Regulatory Services for Generics and Biosimilars Drugs: Global Market, 2020-2030
- 19.2 Leading National Markets for CRO Regulatory Services for Generics and Biosimilars Drugs 2020-2030
- 19.3 Leading Companies in the CRO Regulatory Services for Generics
- and Biosimilars Drugs 2020-2030
- List of Figures
- Figure 1 CRO Regulatory Services For Generics And Biosimilars Drugs Segmentation By Service, 2019
- Figure 2 Global CRO Regulatory Services for Generics and Biosimilar Drugs Market Overview
- Figure 3 Porter’s Five Forces Analysis
- Figure 4 Porter’s Five Force Analysis of the CRO Regulatory Services for Generics and Biosimilar Drugs Market, 2019
- Figure 5 SWOT Analysis
- Figure 6 PEST Analysis
- Figure 7 Global CRO Regulatory Services for Generics and Biosimilar Drugs Market Forecast Revenue ($bn), AGR (%) 2020-2030
- Figure 8 “V” Shaped Recovery: Global CRO Regulatory Services for Generics and Biosimilar Drugs Market Forecast Revenue ($bn), AGR (%) 2020-2030
- Figure 9 “U” Shaped Recovery: Global CRO Regulatory Services for Generics and Biosimilar Drugs Market Forecast Revenue ($bn), AGR (%) 2020-2030
- Figure 10 “W” Shaped Recovery: Global CRO Regulatory Services for Generics and Biosimilar Drugs Market Forecast Revenue ($bn), AGR (%) 2020-2030
- Figure 11 “L” Shaped Recovery: Global CRO Regulatory Services for Generics and Biosimilar Drugs Market Forecast Revenue ($bn), AGR (%) 2020-2030
- Figure 12 Global CRO Regulatory Services for Generics and Biosimilar Drugs Market Share(%), By Service 2020, 2025, & 2030
- Figure 13 Global CRO Regulatory Services for Generics and Biosimilar Drugs Market Forecast Share(%), By Region 2020, 2025, & 2030
- Figure 14 Global CRO Regulatory Services for Generics and Biosimilars Drugs Market, By Services: Revenues (%), 2020, 2025, & 2030
- Figure 15 Global Regulatory Writing and Publishing Market Forecast: Revenue ($bn) and AGR (%), 2019-2030
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook